The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression by Berx, Geert & Roy, Frans Van
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
ILC = infiltrative lobular breast carcinomas; LCIS = lobular carcinoma in situ; LOH = loss of heterozygosity.
Available online http://breast-cancer-research.com/content/3/5/289
Introduction
Malignant breast cancer is a disease arising in the ductal
and lobular epithelium of the mammary gland. Intercellular
interactions are critical for the dynamic differentiation
processes activated periodically throughout life in normal
breast epithelium, as well as for the induction and mainte-
nance of differentiated tissues in adults. In the past few
years there has been increasing interest in E-cadherin-
mediated cell–cell adhesion and cell–extracellular matrix
adhesion as prime mediators of epithelial differentiation.
E-cadherin is a glycoprotein with a large extracellular
domain comprising five cadherin-motif subdomains, a
single-pass transmembrane segment and a short con-
served cytoplasmic domain, which interacts with several
proteins collectively termed catenins. Several of these
catenins belong to the Armadillo protein family, whereas
α-catenins are vinculin-related molecules. The central
armadillo domain of either β-catenin or plakoglobin (γ-
catenin) interacts directly with a carboxy-terminal cytoplas-
mic domain of the E-cadherin protein. The same armadillo
molecules also interact with α-catenin, and the latter is
directly and indirectly linked to filamentous actin. Another
armadillo catenin, p120ctn, interacts with a more mem-
brane-proximal cytoplasmic domain of cadherins. The
120ctn protein is involved in strengthening cadherin-
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Abstract
E-cadherin is a cell–cell adhesion protein fulfilling a prominent role in epithelial differentiation. Data from
model systems suggest that E-cadherin is a potent invasion/tumor suppressor of breast cancer.
Consistent with this role in breast cancer progression, partial or complete loss of E-cadherin expression
has been found to correlate with poor prognosis in breast cancer patients. The E-cadherin gene
(CDH1) is located on human chromosome 16q22.1, a region frequently affected with loss of
heterozygosity in sporadic breast cancer. Invasive lobular breast carcinomas, which are typically
completely E-cadherin-negative, often show inactivating mutations in combination with loss of
heterozygosity of the wild-type CDH1 allele. Mutations were found at early noninvasive stages, thus
associating E-cadherin mutations with loss of cell growth control and defining CDH1 as the tumor
suppressor for the lobular breast cancer subtype. Ductal breast cancers in general show heterogeneous
loss of E-cadherin expression, associated with epigenetic transcriptional downregulation. It is proposed
that the microenvironment at the invasive front is transiently downregulating E-cadherin transcription.
This can be associated with induction of nonepithelial cadherins.
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containing adhesion junctions [1]. Whereas β-catenin is a
proto-oncogene by virtue of its important role in the Wnt
signaling pathway [2], E-cadherin exerts a potent invasion-
suppressing role in tumor cell lines and in vivo tumor
model systems [3–6]. Forced expression of E-cadherin
decreased proliferation of different mammary carcinoma
cell lines [4,7]. Precancerous hyperproliferation and sus-
tained activation of the Ras-MAPK cascade was recently
found in skin with tissue-specific ablation of α-catenin [8].
Disturbance of E-cadherin expression in
breast cancer
Breast E-cadherin is expressed in normal adults in luminal
epithelial cells, whereas expression of P-cadherin is con-
fined to myoepithelial cells [9,10]. Temporary downregula-
tion of E-cadherin was found in budding lobules invading
the stroma of breast tissue [11]. Changes in the normal
expression pattern of the E-cadherin/catenin complex have
been found in various human cancers. In breast cancer,
generally speaking, partial or total loss of E-cadherin
expression correlates with loss of differentiation character-
istics, acquisition of invasiveness, increased tumor grade,
metastatic behavior and poor prognoses [12–15]. Taking
into account the two major histological subtypes of breast
cancer, however, different modes of E-cadherin expres-
sion modulation have been found. While infiltrating ductal
breast cancers mostly show no or only heterogeneously
reduced E-cadherin expression, infiltrative lobular breast
carcinomas (ILC) are, in most cases (85%), completely
E-cadherin-negative [9,16–19]. A significantly lower ratio
of E-cadherin-negative versus E-cadherin-positive ILC
samples has been reported by other workers [19,20]. This
discrepancy could be partly owing to diagnostic variation
as applied to lobular carcinomas [21].
In addition to loss of E-cadherin expression in ILC, simulta-
neous loss of α-catenin expression and β-catenin expres-
sion has been observed [22]. Interestingly, in a minority
(15%) of ILC cases, expression of E-cadherin and
catenins is maintained. In these cases, however, E-cad-
herin expression is atypical because it is nonpolarized (i.e.
tumor cells are stained all over their surface), pointing
toward dysfunction of normal cell–cell adhesion properties
[19,20,22]. Intriguing is the finding that, although primary
ductal and lobular breast cancers can show partial or
complete loss of E-cadherin expression, their derivative
metastases may exhibit strong E-cadherin expression
[23,24]. This suggests that transient E-cadherin downreg-
ulating mechanisms might be involved in malignant
cancers without irreversible mutations of the E-cadherin
gene. The observed switches of cadherin expression in
breast cancer cell lines and tumors are also important
[25,26]. High-grade ductal breast lesions with reduced E-
cadherin expression may show abnormal P-cadherin
expression in luminal cells. Moreover, reduced E-cadherin
expression in breast cancer cells is often associated with
inappropriate expression of N-cadherin and cadherin-11,
which are typically expressed in mesenchymal cells.
Forced expression of N-cadherin in E-cadherin-positive
breast cancer cells correlates with invasion and motility,
suggesting that N-cadherin plays an important role in pro-
moting these malignant features [26].
Irreversible inactivation of E-cadherin in
breast cancer
The efforts to allelotype breast cancer showed concur-
rent loss of heterozygosity (LOH) at multiple chromoso-
mal sites, with LOH at 16q being one of the most
common events (52.3%) in sporadic breast cancer [27].
This points to a significant role of the genes in this chro-
mosomal region to generate sporadic breast cancer. The
E-cadherin gene (CDH1) maps to the human chromo-
some 16q22.1 [28]. Somatically acquired mutations in
CDH1 were found in about 56% of lobular breast tumors,
generally (>90%) in combination with loss of the wild-
type allele, while no mutations were found in ductal
primary breast carcinomas [28,29]. Most of these
somatic mutations result in premature stop codons as a
consequence of insertions, deletions and nonsense muta-
tions. As the majority of these frameshift and nonsense
mutations is predicted to generate secreted E-cadherin
fragments, the functionality of this major cell–cell adhe-
sion protein is lost. Other cancer-confined E-cadherin
mutations also result in crippled proteins. The distinctive
invasive growth pattern, which is typical for lobular breast
cancers, is fully compatible with this functional inactiva-
tion. The finding that loss of E-cadherin immunoreactivity
and corresponding mutations are already present in early
noninvasive lobular carcinoma in situ (LCIS) lesions is
intriguing [18]. This suggests a genuine tumor suppres-
sor role for E-cadherin during sporadic breast cancer
development, in addition to the previously described role
as an invasion suppressor. Experimental evidence for an
effective role in control of cell proliferation comes from in
vitro and  in vivo experiments with E-cadherin-negative
breast cancer cells. Forced E-cadherin expression in
these cells resulted in significant growth inhibition both in
cell culture and as tumors in mice [4]. This diminished
growth capacity could be associated with elevated
expression of the cyclin-dependent kinase inhibitor
p27KIP1 [7].
The molecular basis of mixed types of ductal/lobular
breast cancers remains, however, enigmatic. Such mixed
breast cancer type occurs in both advanced and in situ
stages. This might indicate that the lobular component in
these particular breast tumors could originate from ductal
carcinomas (in situ or infiltrative variants) through E-cad-
herin inactivation. This would be fully compatible with
earlier findings in mixed gastric carcinomas where E-cad-
herin mutations were exclusively observed in the diffuse
component of the tumors [30].c
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Complete loss of E-cadherin expression may be expected
to result in increased levels of free cytoplasmic or nuclear
β-catenin. The nuclear forms of β-catenin accumulate in
colorectal cancers due to mutations in the Wnt signaling
pathway, including truncating adenomatous polyposis coli
mutation and stabilizing β-catenin mutations [2]. The
outcome is interaction of β-catenin with transcription
factors of the lymphoid enhancer factor–T-cell factor
family in the nucleus and modulation of gene expression.
The concomitant loss of α-catenin expression and β-
catenin expression in ILCs with mutated CDH1 gene [22],
however, rules out the possible activation of Wnt signaling
through accumulating free cytoplasmic or nuclear β-
catenin in these particular breast cancers. Indeed, it has
recently become clear that cell lines of either lobular or
ductal origin with loss of E-cadherin expression do not
show enhanced Wnt signaling [31]. Nonetheless, expres-
sion of a stabilized, transcriptionally active form of β-
catenin in the mammary gland of transgenic mice affected
normal gland differentiation and induced readily multiple
aggressive adenocarcinomas with overexpression of both
c-Myc and cyclin D1 [32]. Surprisingly, for ILCs with a
defective E-cadherin/catenin complex but lacking
detectable E-cadherin mutations, no evidence has so far
been found for mutational inactivation of α-catenin or β-
catenin [33]. In conflict with mutational data from primary
tumors is also the report that 20% (3/15) of breast cancer
cell lines of ductal origin carry inactivating E-cadherin
mutations in combination with LOH [31]. The reason for this
discrepancy is presently unclear: it could be a reflection of
deviating histopathological diagnosis, or it may be owing to
tumor heterogeneity in primary ductal carcinomas with a
hardly detectable minority of cells of the ILC type with E-
cadherin mutations. Moreover, the existence of ductal
breast cancer cell lines with loss of functional E-cadherin
may be the result of in vitro clonal selection due to growth
advantage provided by inactivation of the E-cadherin gene.
The often-occurring inactivation of the CDH1 gene in spo-
radic ILC of the breast as well as the high frequency of
multicentric and bilateral ILC or LCIS strongly suggested
E-cadherin as a good candidate tumor suppressor gene
for a fraction of the hereditary breast cancers [34,35].
E-cadherin germ-line mutations have been identified in a
number of families with inherited predisposition to diffuse
gastric carcinomas [36,37]. A subset of patients with this
inherited cancer syndrome, also termed hereditary diffuse
gastric cancer syndrome, exhibit other cancers such as
breast and colorectal cancer. Constitutional CDH1 muta-
tions in a single family have so far been associated with
the development of metachronous diffuse gastric cancer
and breast cancer of the lobular subtype [38]. The reason
for the apparent predominance of gastric cancer in these
families is so far unknown; it may be the consequence of a
differential inactivation efficiency of the second allele by
genetic or epigenetic mechanisms [39]. Patients
diagnosed with LCIS do consistently show LOH for
16q22.1 and loss of E-cadherin expression, and somatic
mutations in the CDH1 gene of LCIS cells were indeed
reported [18,22]. Nevertheless, no constitutional muta-
tions could be identified in a large series of LCIS [40].
Reduced transcription of E-cadherin in breast
cancer
For most of the primary breast cancers and cell lines of
the ductal histotype, no E-cadherin mutations could be
identified despite the fact that these tumors often show
strikingly reduced E-cadherin gene and protein expres-
sion. Possible mechanisms to explain this reduced expres-
sion include chromatin rearrangements, hypermethylation
and alterations in trans-factor binding [41,42]. Hyper-
methylation of the CDH1 promoter and the overlapping
5′ CpG island has been demonstrated to correlate with
loss of E-cadherin expression at the transcriptional level
for various breast cancer cell lines and primary ductal
breast cancers [43]. Moreover, several infiltrative lobular
cancers were recently reported to carry methylated CDH1
promoter sequences [20]. This might serve as a second
gene inactivation event, in combination with either LOH or
somatic  CDH1 mutations, although biallelic methylation
was also assumed to occur. Treatment of two breast
cancer cell lines with the DNA methylation inhibitor 5-aza-
2′-deoxycytidine resulted in slight upregulation of E-cad-
herin mRNA and protein levels [43]. Interestingly,
heterogeneous methylation of this 5′ CpG island has been
reported to markedly increase during malignant progres-
sion from ductal carcinoma in situ to metastatic lesions
[44]. These epigenetic changes appear to be dynamic as
they can be mimicked in vitro depending on microenviron-
mental conditions favoring either homotypic cell adhesion
(growth as spheroids) or in vitro invasion [45].
It is not yet clear, however, whether the direct involvement
of hypermethylation as a predominant mechanism in sup-
pressing E-cadherin gene expression can be extrapolated
to most breast cancers showing a methylated gene pro-
moter. It is indeed intriguing that E-cadherin expression
could not be restored in somatic cell hybrids resulting
from fusions between E-cadherin-positive cell lines and
cell lines with a methylated inactive E-cadherin promoter
[46]. Besides this dominant repression, the inability to
reactivate E-cadherin expression by 5-aza-2′-deoxycytidine
treatment has been seen, which indicates that loss of
E-cadherin mRNA expression is not only attributable to
hypermethylation [47]. Support for a trans-acting repres-
sion mechanism has recently been found by identification
of the transcription factor Snail, binding directly to E2
boxes in the E-cadherin promoter and potently repressing
its transcription [48,49]. Snail is highly expressed in
E-cadherin-negative breast cancer cell lines, including
those with methylated 5′ CpG islands. In this context, it is
interesting to mention that high integrin-linked kinase
Available online http://breast-cancer-research.com/content/3/5/289expression in mammary epithelial cells induced an epithe-
lial→mesenchymal transition, which was associated with
loss of E-cadherin expression [50]. It recently became
apparent that integrin-linked kinase activates the Snail pro-
moter in colorectal cancer cell lines with adenomatous
polyposis coli mutations [51]. Moreover, E-cadherin gene
transcription has been reported to be inhibited in breast
cancer cells by overexpression of erbB2, a proto-onco-
gene frequently overexpressed in breast cancers [52].
Transforming growth factor-β, which plays an important
inhibitory role in lobuloalveolar development on overex-
pression in vivo in mammary gland [53], is also able to
repress E-cadherin transcription in mammary gland cells
[54,55]. It is therefore most interesting that the two-
handed E2-box binding zinc finger protein SIP1 (ZEB2),
initially isolated on the basis of its interaction with trans-
forming growth factor-β-regulated Smad proteins, can
downregulate E-cadherin and induce invasiveness [56].
Various E-cadherin-negative breast and colon cancer cell
lines express SIP1, including those with a methylated
E-cadherin promoter. It may therefore be worthwhile to
seek Snail and SIP1-inducing factors in the microenviron-
ment of invasive parts of malignant breast tumors.
Conclusions
Today, it is doubtless that inactivation of E-cadherin has an
important role in the development of part of the sporadic
breast cancers. The high incidence of complete and irre-
versible inactivation of E-cadherin in infiltrative lobular breast
cancer evidences the role of E-cadherin as a genuine tumor
suppressor in this specific histological subclass of sporadic
breast cancers. This is further supported by the finding that
E-cadherin is already inactivated in early noninvasive LCIS,
which contradicts a model with a restricted role for E-cad-
herin as only an invasion suppressor. Heterogeneous loss of
E-cadherin expression is generally observed in ductal breast
cancers. This negative regulation seems to be reversible at
the transcriptional level, allowing re-expression at the sec-
ondary metastatic tumor site. As the underlying mechanisms
and relevant key molecules become progressively identified,
this opens the possibility to develop anti-tumor and anti-
invasion strategies aimed at functional upregulation of E-
cadherin in breast cancers.
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